Important role of 3-methoxytyramine in the inhibition of cocaine sensitization by 1-methyl-1,2,3,4-tetrahydroisoquinoline: an in vivo microdialysis study
Tóm tắt
1-Methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) is an endogenous compound with neuroprotective and antidopaminergic activities. Our previous research has shown that 1MeTIQ prevents morphine addiction and abates the expression of the reinstatement of cocaine self-administration. The current study investigated the mechanism of action of 1MeTIQ that is responsible for its considerable anticraving potential. Accordingly, we performed behavioral tests that measured the influence of 1MeTIQ on the locomotor activity of rats (Wistar) after a single cocaine (15 mg/kg, ip) dose and during cocaine sensitization (15 mg/kg, ip). In a neurochemical study, we examined the influence of 1MeTIQ on dopamine release in the rat striatum after a single cocaine administration and during cocaine sensitization using an in vivo microdialysis methodology. The data showed that 1MeTIQ (50 mg/kg, ip) only slightly inhibited cocaine-induced hyperactivity but completely antagonized the expression of locomotor cocaine sensitization. The in vivo micro-dialysis study demonstrated that the administration of 1MeTIQ before the acute cocaine injection intensified the cocaine-induced increase in dopamine release and produced a huge and long-lasting elevation of the extraneuronal concentration of dopamine (by approximately 1400%, p < 0.01) in the rat striatum. A significant increase in 3-methoxytyramine (3-MT) (by approximately 400%, p < 0.01) was also observed. During the expression of cocaine sensitization, the administration of 1MeTIQ before the reminder dose of cocaine produced an additional elevation of dopamine release but considerably more strongly increased the concentration of 3-MT in the synaptic cleft (by about 800%, p < 0.01). In light of these data and of our earlier in vitro and in vivo experiments showing a physiological role of 3-MT in the inhibitory regulation of excessive stimulation, we suggest that locomotor hyperactivity is dependent not only on dopamine concentration in the extracellular space, but also on the ratio of [DA/3-MT]. 1MeTIQ administered before the reminder dose of cocaine to cocaine-experienced rats plainly normalized the [DA/3-MT] ratio, which was increased by cocaine, and this effect may be responsible for its anti-addictive action. The results strongly support the view that 1MeTIQ may have a more general anti-abuse potential, and the extraneuronal metabolite of dopamine, 3-MT, may play a crucial role in its anti-craving effects.
Tài liệu tham khảo
Akimoto K, Hamamura T, Otsuki S: Subchronic cocaine treatment enhances cocaine-induced dopamine efflux, studies by in vivo intracerebral dialysis. Brain Res, 1989, 490, 339–344.
Antkiewicz-Michaluk L, Filip M, Kostowski W, Patsenka A, Popik P, Przegaliński E, Wróbel M: 1-Methyl- 1,2,3,4-tetrahydroisoquinoline attenuates ethanol, cocaine and morphine addiction in behaviora models: neurochemical correlates. Acta Neurobiol Exp, 2005, 65, P3.01 p. 321.
Antkiewicz-Michaluk L, Filip M, Michaluk J, Romańska I, Przegaliński E, Vetulani J: An endogenous neuropro-tectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats. J Neural Transm, 2007, 114, 307–317.
Antkiewicz-Michaluk L, Karolewicz B, Romańska I, Michaluk J, Bojarski A, Vetulani J: 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol, 2003, 466, 263–269.
Antkiewicz-Michaluk L, Łazarewicz JW, Patsenka A, Kajta M, Ziemińska E, Salińska E, Wąsik A et al.: The mechanism of 1,2,3,4-tetrahydroisoquinolines neu-roprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem, 2006, 97, 846–856.
Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, Romańska I, Lorenc-Koci E, Otha S, Vetulani J: Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem, 2001, 78, 100–108.
Antkiewicz-Michaluk L, Michaluk J, Romańska I, Papla I, Vetulani J: Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol. J Neural Transm, 2000, 107, 1009–1019.
Antkiewicz-Michaluk L, Ossowska K, Romańska I, Michaluk J, Vetulani J: 3-Methoxytyramine, an extraneu-ronal dopamine metabolite plays a physiological role in the brain as an inhibitory regulator of catecholaminergic activity. Eur J Pharmacol, 2008, 599, 32–35.
Antkiewicz-Michaluk L, Romańska I, Papla I, Michaluk J, Bakalarz M, Vetulani J, Krygowska-Wajs A, Szczudlik A: Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and sal-solinol in dopaminergic structures of rat brain. Neuroscience, 2000, 96, 59–64.
Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romańska I, Bojarski A, Vetulani J: Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neu-rodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsy-chopharmacol, 2004, 7, 155–163.
Berger SP, Hall S, Mickalian JD, Reid MS, Crawford CA, Delucchi K, Carr K, Hall S: Haloperidol antagonism of cue-elicited cocaine craving. Lancet, 1996, 347, 504–508.
Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S et al.: Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem, 2003, 46, 3822–3839.
Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin F: One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch Gen Psychiatry, 1994, 51, 989–997.
Cornish JL, Duffy P, Kalivas PW: A role for nucleus ac-cumbens glutamate transmission in the relapse to cocaine-seeking behavior. Neuroscience, 1999, 93, 1359–1367.
De Montis MG, Gambarana C, Ghiglieri O, Tagliamonte A: Reversal of stable behavioural modifications through NMDA receptor inhibition in rats. Behav Pharmacol, 1995, 6, 562–567.
De Wit H, Wise RA: Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can J Psychol, 1977, 31, 195–203.
Di Chiara G: The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend, 1995, 38, 95–137.
Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia S, Tassin J-P: a1b-Adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci, 2002, 22, 2873–2884.
Elkashef A, Fudala PJ, Gorgon L, Li SH, Kahn R, Chiang N, Vocci F et al.: Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend, 2006, 85, 191–197.
Filip M, Antkiewicz-Michaluk L, Zaniewska M, Frankowska M, Gołda A, Vetulani J, Przegaliński E: Effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline on the behavioral effects of cocaine in rats. J Physiol Pharmacol, 2007, 58, 625–639.
Garcia-Ladona FJ, Cox BF: BP 897, a selective dopa-mine D3 receptor ligand with therapeutic potential for treatment of cocaine-addiction. CNS Drug Rev, 2003, 9, 141–158.
Garzon J, Fuentes J, Del Rio J: Effect of selective monoamine oxidase inhibitor drugs on morphine tolerance and physical dependence in mice. Neuropharmacol-ogy, 1979, 18, 531–536.
Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol, 2006, 17, 151–159.
Gawin FH: Cocaine addiction: psychology and neurophysiology. Science, 1991, 251, 1580–1586.
Gifford AN, Johnson KM: Effect of chronic cocaine treatment on D2 receptors regulating the release of dopa-mine and acetylcholine in the nucleus accumbens and striatum. Pharmacol Biochem Behav, 1992, 41, 841–846.
Goldstein RZ, Volkow ND: Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry, 2002, 159, 1642–1652.
Grasing K, He S: Effects of high-dose of selegiline on morphine reinforcement and precipitated withdrawal in dependent rats. Behav Pharmacol, 2005, 16, 1–13.
Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y: Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci, 2003, 23, 742–747.
Guan LC, Robinson TE, Becker JB: Sensitization of rotational behavior produced by a single exposure to cocaine. Pharmacol Biochem Behav, 1985, 22, 901–903.
Heidbreder CA, Hagan JJ: Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving. Curr Opin Pharmacol, 2005, 5, 107–118.
Heikkila RE, Manzino L: Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur J Pharmacol, 1984, 103, 241–248.
Hemby SE, Smith JE, Dworkin SI: The effects of eticlo-pride and naltrexone on responding maintained by food, cocaine, heroin and cocaine/heroin combinations in rats. J Pharmacol Exp Ther, 1996, 277, 1247–1258.
Houtsmuller EJ, Notes LD, Newton T, van Sluis N, Chiang N, Elkashef A, Bigelow GE: Transdermal sele-giline and intravenous cocaine: safety and interactions. Psychopharmacology, 2004, 172, 31–40.
Howell LL, Wilcox KM: The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther, 2001, 298, 1–6.
Howell LL, Wilcox KM, Lindsey KP, Kimmel HL: Olanzapine-induced suppression of cocaine self-administration in rhesus monkeys. Neuropsychopharmacology, 2006, 31, 585–593.
Hurd YL, Weiss F, Koob GF, Ungerstedt N-EU: Cocaine reinforcement and extracellular dopamine overflow in rat nucleus accumbens: an in vivo microdialysis study. Brain Res, 1989, 498, 199–203.
Ishiwata K, Koyanagi Y, Abe K, Kawamura K, Taguchi K, Saitoh T, Toda J et al.: Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D2 receptors in the mouse striatum. J Neurochem, 2001, 79, 868–876.
Jiménez-Rivera CA, Felieu-Mojer M, Vazquez-Torres R: Alpha-noradrenergic receptors modulate the development and expression of cocaine sensitization. Ann NY Acad Sci, 2006, 1074, 390–402.
Juhila J, Honkanen A, Sallinen J, Haapalinna A, Korpi ER, Scheinin M: (X2A-Adrenoceptors regulate D-amphetamine-induced hyperactivity and behavioural sensitization in mice. Eur J Pharmacol, 2005, 517, 74–83.
Kalivas PW: Glutamate systems in cocaine addiction. Curr Opin Pharmacol, 2004, 4, 23–29.
Kalivas PW, Duffy P: The effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse, 1990, 5, 48–58.
Kalivas PW, Duffy P: Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci, 1993, 13, 266–275.
Kalivas PW, Duffy P, Du Mars LA, Skinner C: Behavioral and neurochemical effects of acute and daily cocaine administration in rats. J Pharmacol Exp Ther, 1988, 245, 485–492.
Karoum F, Chrapusta SJ, Brinjak R, Hitri A, Watt RJ: Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Br J Pharmacol, 1994, 113, 1391–1399.
Karoum F, Chrapusta SJ, Egan MF: 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem, 1994, 63, 972–979.
Kleven MS, Woolverton WL: Effects of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys. Drug Alcohol Depend, 1993, 31, 149–58.
Kohno M, Otha S, Hirobe M: Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. Biochem Biophys Res Commun, 1986, 140, 448–454.
Koob GF, Nestler EJ: The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci, 1997, 9, 482–497.
Kotake Y, Taguchi R, Okuda K, Sekiya Y, Tasaki Y, Hirobe M, Ohta S: Neuroprotective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on cultured rat mesen-cephalic neurons in the presence or absence of various neurotoxins. Brain Res, 2005, 1033, 143–50.
Kuhar MJ, Ritz MC, Boja JW: The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci, 1991, 14, 299–302.
Le Foll B, Goldberg SR, Sokoloff P: The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology, 2005, 49, 525–541.
Le Foll B, Schwartz JC, Sokoloff P: Dopamine D3 receptor agents as potential new medications for drug addictions. Eur Psychiatry, 2000, 15, 140–146.
Lienau AK, Kuschinsky K: Sensitization phenomena after repeated administration of cocaine or D-amphetamine in rats: associative and non-associative mechanisms and the role of dopamine in the striatum. Naunyn Schmiede-berg’s Arch Pharmacol, 1997, 355, 531–537.
Mach UR, Hackling AE, Perachon S, Ferry S, Wermuth CG, Schwartz JC, Sokoloff P, Stark H: Development of novel 1,2,3,4-tetrahydroisoquinoline derivatives and closely related compounds as potent and selective dopamine D3 receptor ligands. Chembiochem, 2004, 5, 508–518.
Mc Naught KS, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Meltzer HY: An overview of the mechanism of action of clozapine. J Clin Psychiat, 1994, 55, 47–52.
Meil WM, Schechte MD: Olanzapine attenuates the reinforcing effects of cocaine. Eur J Pharmacol, 1997, 340, 17–26.
Moore RJ, Vinsant SL, Nader MA, Porrino LJ, Friedman DP: Effect of cocaine self-administration on striatal do-pamine D1 receptors in rhesus monkeys. Synapse, 1998, 28, 1–9.
Moore RJ, Vinsant SL, Nader MA, Porrino LJ, Friedman DP: Effect of cocaine self-administration on striatal do-pamine D2 receptors in rhesus monkeys. Synapse, 1998, 30, 88–96.
Narayanan S, Willins D, Dalia A, Wallace L, Uretsky N: Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol Biochem Behav, 1996, 54, 565–573.
Ossowska K, Wardas J, Kuter K, Nowak P, Dąbrowska J, Bortel A, Labus Ł et al.: Influence of paraquat on dopa-minergic transporter in the rat brain. Pharmacol Rep, 2005, 57, 330–335.
Patsenka A, Antkiewicz-Michaluk L: Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds -1,2,3,4-tetrahydroisoquinoline alkaloids. Pol J Pharmacol, 2004, 56, 727–734.
Peris J, Zahniser NR: One injections of cocaine produces a long-lasting increase in [3H]-dopamine release. Pharmacol Biochem Behav, 1987, 27, 533–535.
Pettit HO, Pan H-T, Parsons LH, Justice JB Jr: Extracellular concentration of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem, 1990, 55, 798–804.
Pierce RC, Kalivas PW: A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev, 1997, 25, 192–216.
Pietraszek M, Michaluk J, Romańska I, Wąsik A, Gołembiowska K, Antkiewicz-Michaluk L: 1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat. Neurotox Res, 2009, 16, 390–407.
Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC et al.: Selective inhibition of cocaine-seeking behavior by a partial dopamine D3 receptor agonist. Nature, 1999, 400, 371–375.
Preti A: BP-897 Bioprojet. Curr Opin Investig Drugs, 2000, 1, 110–115.
Pulvirenti L, Maldonado-Lopez R, Koob GF: NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Res, 1992, 594, 327–330.
Reith ME, Meisler BE, Sershen H, Lajtha A: Structural requirements for cocaine congeners to interact with do-pamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem Pharmacol, 1986, 35, 1123–1129.
Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ: Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science, 1987, 237, 1219–1223.
Robinson TE, Berridge KC: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev, 1993, 18, 247–291.
Schiffer WK, Azmoodeh M, Gerasimov M, Volkow ND, Fowler JS, Dewey SL: Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine. Synapse, 2003, 48, 35–38.
Segal DS, Geyer MA, Schuckit MA: Stimulant-induced psychosis: an evaluation of animal methods. Essays Neurochem Neuropharmacol, 1981, 5, 95–129.
Segal DS, Kuczenski R: Repeated cocaine administration induces behavioral sensitization and corresponding decreased extracellular dopamine responses in caudate and accumbens. Brain Res, 1992, 577, 351–355.
Smelson DA, Williams J, Ziedonis D, Sussner BD, Losonczy MF, Engelhart C, Kaune M: A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat, 2004, 27, 45–49.
Tzschentke TM, Schmidt WJ: Glutamatergic mechanisms in addiction. Mol Psychiatry, 2003, 8, 373–382.
Vetulani J: Drug addiction. Part II. Neurobiology of addiction. Pol J Pharmacol, 2001, 53, 303–317.
Vetulani J, Antkiewicz-Michaluk L, Nalepa I, Sansone M: A possible physiological role for cerebral tetrahydroiso-quinolines. Neurotox Res, 2003, 5, 147–215.
Villegier AS, Drouin C, Bizot JC, Marien M, Glowinski J, Colpaert F, Tassin JP: Stimulation of postsynaptic a1b- and a2-adrenergic receptors ampliflies dopamine-mediated locomotor activity in both rats and mice. Synapse, 2003, 50, 277–284.
Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S et al.: Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature, 1997, 386, 827–830.
Wąsik A, Patsenka A, Antkiewicz-Michaluk L: An endogenous compound 1-methyl-1,2,3,4-tetrahydroiso-quinoline prevents the morphine addiction in rat: the view on neurochemical mechanism of action. Eur Neuropsychopharmacol, 2005, 15, Suppl, 22–23.
Wąsik A, Romańska I, Antkiewicz-Michaluk L: The effect of an endogenous compoud 1-methyl-1,2,3,4-tetra-hydroisoquinoline on morphine-induced analgesia, dependence and neurochemical changes in dopamine metabolism in rat brain structures. J Physiol Pharmacol, 2007, 58, 235–252.
Wise RA: Neural mechanisms of the reinforcing action of cocaine. NIDA Res Monogr, 1984, 50, 15–33.
Woolverton WL: Effects of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribe-dil by rhesus monkeys. Pharmacol Biochem Behav, 1986, 24, 531–535.
Woolverton WL, Johnson KM: Neurobiology of cocaine abuse. Trends Pharmacol Sci, 1992, 13, 193–200.
Zhang Y, Loonam TM, Noailles PA, Angulo JA: Comparison of cocaine- and amphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions. Ann NY Acad Sci, 2001, 937, 93–120.